Signup for our free newsletter:

Marijuana Minute: Canadian Bioceutical Corporation (CSE: BCC) Grabs $10M and another reason Cannabis Prohibition is a Human Rights Violation

Written By Jeff Siegel

Posted October 25, 2017

The Canadian Bioceutical Corporation (CSE: BCC) has announced that it has utilized $10 million of a $25 million revolving credit facility, which will be used to continue its expansion efforts in Massachusetts and Maryland.

BCC is one of those under-the-radar cannabis stocks that hasn’t been given nearly the amount of attention it deserves. I’m actually a fan of this company as it has a pretty significant footprint in some of the more lucrative cannabis markets in the U.S. and abroad.

The company has exposure to Nevada through an acquisition of GreenMart of Nevada, which is an award winning licensed cultivation, production and wholesale business in Vegas. It also has exposure to the Arizona market and the Massachusetts market, which is one of the most lucrative in the country as there are strict limits on licenses.

As well, BCC has recently entered into a joint venture with Israeli-based Panaxia Pharmaceuticals, which is a manufacturer of pharmaceutical dosage forms incorporating cannabinoids as an active ingredient. The company is part of a larger group of companies which have manufactured pharmaceuticals for more than 40 years.

The stock’s trading at around $0.40 right now. By this time next year, BCC will be trading in excess of $0.80 a share.

Here’s a short analysis I did on the company back in May:

Save your Child, Go to Jail?!!

Can you imagine being faced with the reality of going to jail for trying to save your child’s life?

That’s the scenario Callie Blackwell was faced with when she decided to give her son cannabis oil in an effort to save his life.

Make no mistake, cannabis prohibition is a human rights violation.

Check out the full story here …